BeOne Medicines Ltd. beat EPS estimates 50% of the time across 16 reported quarters (8 beats, 8 misses), averaging +0.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $1.40 | $2.05 | +46.4% | Beat | |
| Q1 FY26 | not reported | $1.96 | not reported | not reported | |
| Q4 FY25 | not reported | $0.58 | not reported | not reported | Q4 FY25 call · transcript |
| Q3 FY25 | $0.72 | $1.09 | +51.4% | Beat | |
| Q2 FY25 | $0.48 | $0.84 | +75.0% | Beat | |
| Q1 FY25 | not reported | $1.22 | not reported | not reported | |
| Q4 FY24 | $-0.88 | $-1.43 | -62.5% | Miss | |
| Q3 FY24 | $-0.88 | $-1.15 | -30.7% | Miss | |
| Q2 FY24 | $-2.10 | $-1.15 | +45.2% | Beat | |
| Q1 FY24 | $-2.98 | $-2.41 | +19.1% | Beat | |
| Q4 FY23 | $-2.36 | $-3.53 | -49.6% | Miss | |
| Q3 FY23 | not reported | $2.01 | not reported | not reported |
Back to ONC overview · ONC holders · ONC KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.